|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2003-4-1
|
|
pubmed:abstractText |
Patients with diabetes have increased risk for adverse cardiovascular events. Angiotensin-converting enzyme inhibitors are protective in type 1 diabetes. However, no definitive studies have examined the use of angiotensin-receptor blockers in patients with type 2 diabetes and overt nephropathy. The primary outcomes of the Irbesartan Diabetic Nephropathy Trial were doubling of serum creatinine levels, end-stage renal disease, and death from any cause.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1539-3704
|
|
pubmed:author |
pubmed-author:BerlTomasT,
pubmed-author:DruryPaul LPL,
pubmed-author:EsmatjesEnricE,
pubmed-author:GoldhaberSamuel ZSZ,
pubmed-author:HricikDonaldD,
pubmed-author:HunsickerLawrence GLG,
pubmed-author:Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group,
pubmed-author:LewisEdmund JEJ,
pubmed-author:LewisJulia BJB,
pubmed-author:LocatelliFrancescoF,
pubmed-author:ParikhChirag RCR,
pubmed-author:PfefferMarc AMA,
pubmed-author:PorushJerome GJG,
pubmed-author:RazItamarI,
pubmed-author:RouleauJean-LucienJL,
pubmed-author:VanhillePhilippeP,
pubmed-author:WiegmannThomas BTB,
pubmed-author:WolfeBernard MBM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
138
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
542-9
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12667024-Amlodipine,
pubmed-meshheading:12667024-Angiotensin II,
pubmed-meshheading:12667024-Angiotensin Receptor Antagonists,
pubmed-meshheading:12667024-Antihypertensive Agents,
pubmed-meshheading:12667024-Biphenyl Compounds,
pubmed-meshheading:12667024-Calcium Channel Blockers,
pubmed-meshheading:12667024-Cardiovascular Diseases,
pubmed-meshheading:12667024-Creatinine,
pubmed-meshheading:12667024-Diabetes Mellitus, Type 2,
pubmed-meshheading:12667024-Diabetic Angiopathies,
pubmed-meshheading:12667024-Diabetic Nephropathies,
pubmed-meshheading:12667024-Double-Blind Method,
pubmed-meshheading:12667024-Female,
pubmed-meshheading:12667024-Follow-Up Studies,
pubmed-meshheading:12667024-Humans,
pubmed-meshheading:12667024-Hypertension,
pubmed-meshheading:12667024-Kidney Failure, Chronic,
pubmed-meshheading:12667024-Male,
pubmed-meshheading:12667024-Middle Aged,
pubmed-meshheading:12667024-Placebos,
pubmed-meshheading:12667024-Risk Factors,
pubmed-meshheading:12667024-Tetrazoles,
pubmed-meshheading:12667024-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
|
|
pubmed:affiliation |
University of Colorado Medical School, Denver, Colorado, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
